MedTrace Logo

ANAVEX2-73 Study in Patients With Rett Syndrome

NCT03941444 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-01-27

No results posted yet for this study

Summary

ANAVEX2-73-RS-002 is a Phase 3, double-blind, randomized, placebo-controlled dose escalation safety, tolerability and efficacy study in patients 18 years and older with RTT using endpoints including multiple clinical and exploratory molecular and biochemical measures.

Conditions

Interventions

DRUG

ANAVEX2-73

Liquid oral solution

DRUG

Placebo

Liquid oral solution

Sponsors & Collaborators

  • Anavex Life Sciences Corp.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-06
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03941444 on ClinicalTrials.gov